| Literature DB >> 14744111 |
Deepak Agrawal1, Tingan Chen, Rosalyn Irby, John Quackenbush, Ann F Chambers, Marianna Szabo, Alan Cantor, Domenico Coppola, Timothy J Yeatman.
Abstract
Identifying molecular markers for colon cancer is a top priority. Using a pooled sample approach with Affymetrix GeneChip technology, we assayed colon cancers derived from a series of clinical stages to identify molecular markers of potential prognostic value. Of 12000 genes assessed, osteopontin emerged as the leading candidate tumor progression marker. Osteopontin is a secreted glycoprotein known to bind integrins and CD44. Its actual molecular function remains elusive but its increased expression correlates strongly with tumor progression.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14744111 DOI: 10.1016/j.crvi.2003.09.007
Source DB: PubMed Journal: C R Biol ISSN: 1631-0691 Impact factor: 1.583